Korean J Gastroenterol.  2013 Feb;61(2):63-70. 10.4166/kjg.2013.61.2.63.

Site-specific Colorectal Cancer; How Is It Different?

Affiliations
  • 1Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. hyskim@yonsei.ac.kr

Abstract

One of the most critical characteristics of colorectal cancer (CRC) is the difference between proximal (right-sided colon cancer, RCC) and distal (left-sided colon cancer, LCC) disease. The recent CRC studies showed the unique characteristics of RCC; RCCs were more prevalent in women than men and old patients, and the age difference between RCC and LCC was more apparent in women. Moreover, relatively poor protection against RCC by colonoscopy is a clearly hot issue for alarm. Thus, the left and right colon have been considered as dichotomous or even different organs in the view of molecular, histopathological, epidemiologic and clinical bases for over three decades. However, the evolutionary data suggesting linearity from the rectum to ascending colon beyond the simple right-left dichotomization in the views of cancer molecular features and site-specific clinicopathological differences, support the need for a paradigm shift to the colorectal continuum model rather than the traditional two-colon concept. This new multi-segmental or colorectal continuum hypothesis would provide both the better understanding of the complex etiology of colorectal carcinogenesis and the tailored preventive and therapeutic strategies for CRC including individualized CRC screening programs.

Keyword

Colorectal neoplasms; Site; Molecular; Carcinogenesis; Diagnosis

MeSH Terms

Adenoma/pathology
Age Factors
Colon, Ascending/pathology
Colon, Descending/pathology
Colorectal Neoplasms/genetics/*pathology
Gene Expression Regulation, Neoplastic
Humans
Sex Factors

Figure

  • Fig. 1. Integrative analysis of genomic changes according to the site of colon in 195 CRCs. Hypermutated cancers have near-diploid genomes and are highly enriched for hypermethylation, CIMP phenotype and BRAF (V600E) mutations. Non-hypermutated tumours originating from different sites are virtually indistinguishable from each other on the basis of their copy-number alteration patterns, DNA methylation or gene-expression patterns (citing Fig. 2 in the article of the Cancer Genome Atlas Network [Nature 2012;487:330–337]38 with the original author's permission). CIMP, CpG island methylator phenotype; H, high; L, low; MSI, microsatellite instability; CIN, chromosomal instability.

  • Fig. 2. Schematic illustration of the differences between the two-colon concept and the continuum model. The molecular characteristics including a high degree of CpG island methylator phenotype (CIMP-high), a high degree of microsatellite instability (MSI-high) and BRAF mutation increase linearly from the rectum to the ascending colon according to the new continuum model. Data from numerous previous two-colon studies appear to support the two-colon concept (left, top), even when it is likely that a continuum exists for the measured marker along the proximal- distal axis of the colon (left, bottom). The design of two-colon studies does not permit adequate evaluation of the linearity of marker frequency by colon subsite (modified from Fig. 1 in the article of Yamauchi et al. [Gut 2012; 61:847–854]16 with the original author's permission).


Reference

References

1. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunol-ogy–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011; 8:711–719.
Article
2. Potter J, Hunter D. Colorectal cancer: epidemiology. Potter J, Lindor N, editors. Genetics of colorectal cancer. New York: Springer;2009. p. 5–25.
Article
3. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst. 1980; 65:1201–1207.
4. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350:991–1004.
Article
5. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst. 1985; 75:185–191.
6. Jass J. Pathway and pathology. Potter J, Lindor N, editors. Genetics of colorectal cancer. New York: Springer;2009. p. 97–121.
7. Jensen OM. Different age and sex relationship for cancer of subsites of the large bowel. Br J Cancer. 1984; 50:825–829.
Article
8. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010; 53:57–64.
Article
9. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev. 2012; 21:411–416.
Article
10. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011; 29:1261–1270.
Article
11. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–Medicare data. J Clin Oncol. 2011; 29:4401–4409.
Article
12. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002; 101:403–408.
Article
13. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004; 88:261–266.
Article
14. Carethers JM. One colon lumen but two organs. Gastroenterology. 2011; 141:411–412.
Article
15. Albuquerque C, Bakker ER, van Veelen W, Smits R. Colorectal cancers choosing sides. Biochim Biophys Acta. 2011; 1816:219–231.
Article
16. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012; 61:847–854.
Article
17. Beart RW, Melton LJ 3rd, Maruta M, Dockerty MB, Frydenberg HB, O'Fallon WM. Trends in right and left-sided colon cancer. Dis Colon Rectum. 1983; 26:393–398.
Article
18. Butcher D, Hassanein K, Dudgeon M, Rhodes J, Holmes FF. Female gender is a major determinant of changing subsite distribution of colorectal cancer with age. Cancer. 1985; 56:714–716.
Article
19. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet. 1989; 2:353–356.
Article
20. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990; 113:779–788.
Article
21. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009; 150:1–8.
Article
22. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol. 2010; 105:1189–1195.
Article
23. Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol. 2010; 105:2656–2664.
Article
24. Neugut AI, Lebwohl B. Colonoscopy vs sigmoidoscopy screening: getting it right. JAMA. 2010; 304:461–462.
25. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10:13–27.
Article
26. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997; 386:623–627.
Article
27. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009; 361:2449–2460.
28. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011; 60:116–129.
Article
29. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011; 2011:902674.
Article
30. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8:686–700.
Article
31. Wong JJ, Hawkins NJ, Ward RL, Hitchins MP. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2011; 24:396–411.
Article
32. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012; 1825:77–85.
Article
33. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005; 129:837–845.
Article
34. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38:787–793.
Article
35. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008; 3:e3698.
Article
36. Tanaka N, Huttenhower C, Nosho K, et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol. 2010; 177:2731–2740.
Article
37. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011; 225:336–343.
Article
38. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330–337.
39. Thörn M, Bergström R, Kressner U, Sparén P, Zack M, Ekbom A. Trends in colorectal cancer incidence in Sweden 1959–93 by gender, localization, time period, and birth cohort. Cancer Causes Control. 1998; 9:145–152.
40. Chauvenet M, Cottet V, Lepage C, Jooste V, Faivre J, Bouvier AM. Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population. BMC Cancer. 2011; 11:282.
Article
41. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010; 102:1012–1022.
Article
42. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a metaanalysis of prospective studies. Int J Cancer. 2006; 119:2657–2664.
Article
43. Rothwell PM, Wilson M, Elwin CE, et al. Longterm effect of aspirin on colorectal cancer incidence and mortality:20-year fol-low-up of five randomised trials. Lancet. 2010; 376:1741–1750.
44. Morimoto LM, Newcomb PA, Ulrich CM, Bostick RM, Lais CJ, Potter JD. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002; 11:1012–1018.
45. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst. 2000; 92:1831–1836.
Article
46. LaPointe LC, Dunne R, Brown GS, et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics. 2008; 33:50–64.
Article
47. Worthley DL, Whitehall VL, Buttenshaw RL, et al. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene. 2010; 29:1653–1662.
Article
48. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut. 2010; 59:794–799.
Article
49. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011; 6:e18571.
Article
50. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22:292–298.
Article
51. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22:299–306.
Article
52. Li X, LeBlanc J, Truong A, et al. A metaproteomic approach to study human-microbial ecosystems at the mucosal luminal interface. PLoS One. 2011; 6:e26542.
Article
53. Stearns JC, Lynch MD, Senadheera DB, et al. Bacterial bio-geography of the human digestive tract. Sci Rep. 2011; 1:170.
Article
54. Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R. Study Group "Colon/Rectum Carcinoma (Primary Tumor)". Colon carcinoma–classification into right and left sided cancer or according to colonic subsite?–Analysis of 29,568 patients. Eur J Surg Oncol. 2011; 37:134–139.
55. Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol. 2011; 38:284–308.
Article
56. Wray CM, Ziogas A, Hinojosa MW, et al. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009; 52:1359–1366.
Article
57. Park HJ, Kim HS, Won CS, et al. High level quality colonoscopy identifies unique characteristics of colorectal adenomas in asymptomatic older female. Clin Endosc. 2012; 45:S147–S148.
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr